Terodiline

Terodiline

Terodiline is a pharmacological agent that was primarily used as an antispasmodic drug. It was developed by the pharmaceutical industry to treat conditions such as overactive bladder and urinary incontinence. However, it was withdrawn from the market due to serious side effects, including cardiac arrhythmias.

Pharmacology

Terodiline is classified as a calcium channel blocker, which means it inhibits the influx of calcium ions into cardiac muscle and smooth muscle cells. This action relaxes the muscles and reduces muscle spasms, which can help alleviate symptoms of overactive bladder and urinary incontinence.

History

Terodiline was first introduced to the market in the 1980s. However, it was withdrawn from the market in the 1990s after it was found to cause serious side effects, including potentially life-threatening cardiac arrhythmias. The withdrawal of terodiline from the market is often cited as a case study in pharmacovigilance.

Side Effects

The most serious side effect associated with terodiline is the potential to cause cardiac arrhythmias, specifically torsades de pointes. This is a type of ventricular tachycardia that can lead to cardiac arrest and sudden death. Other side effects can include dizziness, nausea, and constipation.

Withdrawal from Market

The withdrawal of terodiline from the market was a significant event in the history of pharmacovigilance. It highlighted the importance of ongoing monitoring of drugs after they have been approved for use, and the need for swift action when serious side effects are identified.

See Also

• Pharmacovigilance
• Calcium channel blocker
• Cardiac arrhythmia
• Torsades de pointes

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!